KOREA WHO
-
-
Vice President of Hana Pharm
Cho Dong-hoon
Anesthesia Market Leader Accelerates Southeast Asia Expansion with Byfavo Injection
-
Last Updated on Mar 31, 2025
-
Vice President of Hana Pharm
Copy Url : https://www.koreawho.com/profile/ChoDonghoon- Life Summary
Cho Dong-hoon is the Executive Vice President in charge of management at Hana Pharm.
He is accelerating efforts to expand into the Southeast Asian market and secure a lineup of opioid analgesics.
He was born on September 26, 1980, as the eldest son of Cho Kyung-il, the founder of Hana Pharm.
He graduated from the Business Administration Department at the University of Hawaii in the United States and joined Hana Pharm in 2006.
He worked in the Seoul General Hospital Sales Team and served as Head of the Management Division before being promoted to Executive Vice President in 2015.
He gained experience in the pharmaceutical and biotech sectors by working in various departments including sales, marketing, and planning.
He is credited with contributing to the establishment of a stable revenue base for Hana Pharm.
He is overseeing overall management and focusing on strengthening the company’s overseas business.
#ChoDonghoon #HanaPharm #pharmaceuticals #biotech #SoutheastAsia #opioidanalgesics #KoreaPharma #executiveleadership #globalexpansion #businessstrategy
He is accelerating efforts to expand into the Southeast Asian market and secure a lineup of opioid analgesics.
He was born on September 26, 1980, as the eldest son of Cho Kyung-il, the founder of Hana Pharm.
He graduated from the Business Administration Department at the University of Hawaii in the United States and joined Hana Pharm in 2006.
He worked in the Seoul General Hospital Sales Team and served as Head of the Management Division before being promoted to Executive Vice President in 2015.
He gained experience in the pharmaceutical and biotech sectors by working in various departments including sales, marketing, and planning.
He is credited with contributing to the establishment of a stable revenue base for Hana Pharm.
He is overseeing overall management and focusing on strengthening the company’s overseas business.
#ChoDonghoon #HanaPharm #pharmaceuticals #biotech #SoutheastAsia #opioidanalgesics #KoreaPharma #executiveleadership #globalexpansion #businessstrategy
- Life Summary
- Career Highlights & Challenges
- · Hana Pharm’s Ownership Structure
- · Profitability Decline Due to Raw Material Price Increases and Higher SG&A Costs
- · 2024 Year-End Dividend Declared
- · Hana Pharm Owner Family Sells Samjin Pharm Shares
- · Supply Contract Signed for Byfavo Injection in the Philippines
- · Supply Agreement for Byfavo Injection Signed in Indonesia
- · Signed KRW 57.3 Billion Drug Manufacturing Contract with Mundipharma
- · Acquiring Samjin Pharm Shares, Becoming Largest Shareholder
- · Listed on KOSPI
- · History of Hana Pharm
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos